NASDAQ: OKUR
Onkure Therapeutics Inc Stock Ownership - Who owns Onkure Therapeutics?

Insider buying vs selling

Have Onkure Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Nicholas A. SaccomanoPresident and CEO2026-03-2386$4.16
$357.50Sell
Jason A. LeveroneChief Financial Officer2026-03-23301$4.16
$1.25kSell
Nicholas A. SaccomanoPresident and CEO2025-12-2287$2.97
$258.22Sell
Jason A. LeveroneChief Financial Officer2025-12-22302$2.97
$896.34Sell
Jason A. LeveroneChief Financial Officer2025-09-22303$2.62
$794.77Sell
Nicholas A. SaccomanoPresident and CEO2025-09-2288$2.62
$230.82Sell
Nicholas A. SaccomanoPresident and CEO2025-06-2388$2.38
$209.79Sell
Jason A. LeveroneChief Financial Officer2025-06-23303$2.38
$722.35Sell

1 of 1

OKUR insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when OKUR insiders and whales buy or sell their stock.

OKUR Shareholders

What type of owners hold Onkure Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
New Enterprise Associates 15 LP11.85%4,785,494$20.10MInsider
Ra Capital Management LP9.90%3,998,333$16.79MInstitution
Ai Biotechnology LLC9.90%3,998,332$16.79MInsider
Braden Michael Leonard9.67%3,905,210$16.40MInsider
Holdings A. Novo8.24%3,330,337$13.99MInsider
Acorn Capital Advisors LLC7.03%2,839,674$11.93MInstitution
Acorn Bioventures LP7.03%2,839,674$11.93MInsider
Stepstone Group LP6.59%2,660,612$11.17MInstitution
Adar1 Capital Management LLC6.03%2,434,941$10.23MInstitution
Rivervest Venture Fund III LP5.96%2,409,220$10.12MInsider

1 of 3

OKUR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
OKUR48.36%51.64%Net SellingNet Selling
ANTX49.55%50.45%Net SellingNet Selling
ALEC65.14%34.86%Net SellingNet Selling
GALT15.44%84.56%Net SellingNet Buying
EQ64.05%22.25%Net SellingNet Selling

Onkure Therapeutics Stock Ownership FAQ

Who owns Onkure Therapeutics?

Onkure Therapeutics (NASDAQ: OKUR) is owned by 68.13% institutional shareholders, 72.75% Onkure Therapeutics insiders, and 0.00% retail investors. New Enterprise Associates 15 LP is the largest individual Onkure Therapeutics shareholder, owning 4.79M shares representing 11.85% of the company. New Enterprise Associates 15 LP's Onkure Therapeutics shares are currently valued at $20.34M.

If you're new to stock investing, here's how to buy Onkure Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.